M. Lommatzsch, S. Korn, T. Plate, Thorsten Grund, H. Watz
{"title":"摘要:在接受benralizumab治疗的严重嗜酸性粒细胞哮喘(SEA)患者中,患者报告结局(PROs)和身体活动(PA)的早期获益:改善哮喘研究的中期分析","authors":"M. Lommatzsch, S. Korn, T. Plate, Thorsten Grund, H. Watz","doi":"10.1183/13993003.congress-2021.pa3538","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":7848,"journal":{"name":"Airway Pharmacology and Treatment","volume":"112 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Late Breaking Abstract - Early benefits in patient-reported outcomes (PROs) and physical activity (PA) in patients with severe eosinophilic asthma (SEA) treated with benralizumab: interim analysis of the imPROve Asthma study\",\"authors\":\"M. Lommatzsch, S. Korn, T. Plate, Thorsten Grund, H. Watz\",\"doi\":\"10.1183/13993003.congress-2021.pa3538\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":7848,\"journal\":{\"name\":\"Airway Pharmacology and Treatment\",\"volume\":\"112 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-09-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Airway Pharmacology and Treatment\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1183/13993003.congress-2021.pa3538\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Airway Pharmacology and Treatment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1183/13993003.congress-2021.pa3538","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Late Breaking Abstract - Early benefits in patient-reported outcomes (PROs) and physical activity (PA) in patients with severe eosinophilic asthma (SEA) treated with benralizumab: interim analysis of the imPROve Asthma study